In a report released yesterday, Thomas Shrader from BTIG maintained a Buy rating on Sigilon Therapeutics (SGTX – Research Report), with a price target of $7.00. The company’s shares closed yesterday at $1.14.
According to TipRanks, Shrader is an analyst with an average return of -2.7% and a 30.28% success rate. Shrader covers the Healthcare sector, focusing on stocks such as Esperion, Aldeyra Therapeutics, and G1 Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Sigilon Therapeutics with a $6.50 average price target.
See the top stocks recommended by analysts >>
SGTX market cap is currently $37.65M and has a P/E ratio of -0.85.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sigilon Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is developing a new class of therapeutics and functional cures for patients with chronic diseases by providing stable and durable levels of therapeutic molecules to patients.
Read More on SGTX:
